On June 2, 2025, the United States Food and Drug Administration (FDA) announced on its official website the launch of a new generative artificial intelligence (AI) tool named Elsa. The tool is designed to assist various professionals, including scientific reviewers and researchers, in working more efficiently. This innovative tool aims to modernize agency functions and utilize AI capabilities to better serve the American public.
FDA Director Marty Makary said:
"After collaborating with FDA scientific reviewers on a highly successful pilot project, I developed a proactive timeline to implement artificial intelligence agency-wide by June 30. Thanks to the collaboration of internal experts from our various centers, today's launch of Elsa was completed ahead of schedule and within budget."
Elsa is built in a highly secure GovCloud environment, providing FDA employees with a secure platform to access internal files while ensuring all information remains within the agency. These models will not use data submitted by regulated industries for training, thereby protecting the sensitive research and data handled by FDA employees.
FDA Chief Artificial Intelligence Officer Jeremy Walsh stated:
"The release of Elsa marks the arrival of the FDA's artificial intelligence era. Artificial intelligence is no longer a distant promise, but a powerful force that can enhance and optimize the performance and potential of every employee. As we learn how employees are utilizing this tool, our development team will be able to continuously expand its capabilities and grow based on the needs of employees and organizations."
The organization has been using Elsa to expedite the review of clinical trial protocols, shorten the time needed for scientific evaluation, and identify high-priority research targets.Elsa is an AI tool based on a large language model, designed to assist in reading, writing, and summarizing. It can summarize adverse events to support safety assessments, compare tags more quickly, and generate code to help develop non-clinical applications for databases.
The FDA stated that the launch of Elsa is the first step in its overall AI journey. As this tool matures, the FDA plans to integrate more AI technologies into various processes, such as data processing and generative AI functions, to further support the FDA's mission.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
